

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **Abattis Biologix Corp.** (the "Issuer").

Trading Symbol: **FLU**

Number of Outstanding Listed Securities: **54,737,900**

Date: **September 30, 2011**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Presently, the Issuer does not have any cash flow from operations. The Issuer's business activities have been focused on planning and budgeting the Issuer's business plan and matters relating to continuous disclosure requirements and corporate governance.

2. Provide a general overview and discussion of the activities of management.

During September 2011, management focused on planning and budgeting the Issuer's business plan and matters relating to continuous disclosure requirements and corporate governance.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer did not offer any new products, technologies or services during the month of September 2011.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

This item is not applicable to the Issuer for the month of September 2011.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Company is in discussion with several parties to initiate new business relationships, however for the month of September 2011 there have been no new business relationships to report.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

No contracts or agreements were terminated during September 2011.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or dispositions of the Issuer's assets during the month of September 2011.

8. Describe the acquisition of new customers or loss of customers.

This item is not applicable as the Issuer has no customers as of September 2011.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Company has no new developments in the month of September 2011 to announce.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

This item is not applicable for the month of September 2011.

11. Report on any labour disputes and resolutions of those disputes if applicable.

This item is not applicable for the month of September 2011.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

This item is not applicable for the month of September 2011.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

A former director of the Company agreed to the cancellation of an aggregate of \$192,020 in debt which was owed to him by the Company.

The Company entered into a shares for debt agreement with a director with respect to the settlement of an aggregate of \$25,000 in debt by issuance of 500,000 common shares of the Company at a deemed price of \$0.05/share. These shares were issuable in the month of September 2011 but were not issued.

14. Provide details of any securities issued and options or warrants granted.

An aggregate of 500,000 common shares were issued during the month of September 2011 on exercise of warrants.

An aggregate of 1,000,000 stock options were granted to a director of the Company which options are exercisable at a price of \$0.05/share for a period of 5 years during the month of September 2011.

15. Provide details of any loans to or by Related Persons.

This item is not applicable for the month of September 2011.

16. Provide details of any changes in directors, officers or committee members.

During the month of September Mr. Yazan Alhomsy was appointed to the Board of Directors and Gil Schneider and Travis Schneider resigned from the Board of Directors of the Company.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in detail under the heading "Risk Factors" in Section 16 of the Issuer's Listing Statement as filed on December 22, 2010.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated **October 3, 2011**

Mike Withrow

Name of Director or Senior
Officer

"Mike Withrow"

Signature

Director, President & CEO

Official Capacity

<i>Issuer Details</i> Name of Issuer Abattis Biologix Corporation	For Month End September 2011	Date of Report YY/MM/D 2011/10/04
Issuer Address 310 – 885 Dunsmuir Street		
City/Province/Postal Code Vancouver / BC / V6E 4G1	Issuer Fax No. (604) 484-5760	Issuer Telephone No. (604) 538-6650
Contact Name Mike Withrow	Contact Position Director, President & CEO	Contact Telephone No. (604) 538-6650
Contact Email Address mike@abattis.com	Web Site Address www.abattis.com	